abstract |
One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immuno-related diseases, which comprises administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, which comprises administering a compound of the invention. |